Printer Friendly

Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.

Tokyo, Japan, July 4, 2006 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) has established a new pharmaceutical marketing subsidiary in Singapore, "Eisai (Singapore) Pte., Ltd." (ESN), which has launched pharmaceutical import and marketing business.

Previously, Eisai's pharmaceutical import and marketing business in Singapore was handled by Eisai Asia Regional Services Pte. Ltd. (EARS; Head office: Singapore; President: Hiroshi Kimura), but EARS has recently transferred this business to ESN.

By launching operations with this new company, Eisai aims to strengthen its pharmaceutical business in Singapore and further contribute to patients' value in the region.

EARS will renew its operation as a holding company assuming specific function of the seven local subsidiaries in the Asian region, including this newly established ESN in Singapore and existing six others in China, Thailand, Malaysia, the Philippines, Hong Kong and India.

Profile of Eisai (Singapore) Pte. Ltd.
Capital: 300,000 Singapore dollars (approx. 22,000,000 yen)
Location: Singapore
President: Celine Ting
Scope of Business: Import, marketing, and promotion of pharmaceuticals
Capital Alliance: 100% subsidiary of EARS


About Eisai Co., Ltd.

Eisai Co., Ltd. (TSE: 4523)(OTC: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit http://www.eisai.co.jp.

Source: Eisai Co., Ltd.

Contact:
Eisai Co., Ltd.
Corporate Communications Department
+81-3-3817-5120


Copyright [c] 2006 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Geographic Code:9JAPA
Date:Jul 4, 2006
Words:271
Previous Article:Toyota to Enter Hybrid Sedan in 24-hour Race.
Next Article:Kobe Steel to Start Indonesian Trial Project to Upgrade Brown Coal into High-rank Coal; Project to be Carried Out Under the Japan Coal Energy Center.
Topics:


Related Articles
Eisai Submits New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) in Japan.
Eisai Establishes European Strategic Business Hub in the U.K.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
A prescription for success: finding career opportunities in the pharmaceutical industry.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Lawsuit Against Generic Drug Manufacturers Dismissed.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.
Eisai Establishes New Manufacturing Subsidiary in United Kingdom.
A Once-weekly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent, Was Approved.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |